All News

steroid prednisone lab

Corticosteroid Use Hikes CV Risks in Rheumatic Patients

d Jack Cush, MD

UK Clinical Practice Research Datalink population study shows that patients with immune-mediated inflammatory diseases, such as RA, PMR, GCA and IBD, have an augmented risk of CV outcomes with glucocorticoid use; even lower doses had a near doubling of their underlying CVD risk.

Read Article
moneyglobe.jpg

Medicare's 'Most Favored Nation' Drug-Pricing Rule in Limbo

d MedPage Today

The fate of the Trump administration's "most favored nation" (MFN) rule for bringing down prescription drug prices remains uncertain as President-elect Joe Biden prepares to assume office later this month.

Read Article
FINAL 2020 Podcast Graphic

RheumNow Podcast – Lights, Camera, Zoom (1.8.2021)

d Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and favorite blogs from this past week on RheumNow.com.

Read Article
pill pillbox adherence

Adherence to Hydroxychloroquine Lowers Lupus Mortality

d Jack Cush, MD

A lupus cohort study from British Columbia, Canada has shown that medication adherence with hydroxychloroquine (HCQ) is associated with a 71% to 83% lower mortality. 

Read Article
A oatint infected with COVID-19- Yes they should get vaccinated ~90days after infection has resolved.Antibody testing is not needed before you are vaccinated. Evidence suggests that reinfection is uncommon in the 90 days after initial infection. https://t.co/TkcSNx0hF1.

Links:

Dr. John Cush RheumNow ( View Tweet)

Preprint results of the REMAP-CAP trial in the UK shows that IL-6 inhibitors, when given within 24 hrs of ICU entry for COVID-19, lowers mortality rate by 36%. Hosp mortality in 353 TCZ was 28%, 48 sarilumab was 22% in 402 controls was 36%. https://t.co/fkjOz99t0l

Links:

Dr. John Cush RheumNow ( View Tweet)

ACR Convergence 2020 Late Breaking Abstracts available from the ACR "Spotlight" slide give away. 10 slides on COVID, Tyk2 in PsA, FAST febuxostat study, Tofa in AS and novel drugs for SLE and PSS https://t.co/DvcDyusCUR

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is up! Benlysta safety, HCQ lowers thromboses, HCQ adherence, Telemedicine, Actemra in COVID,, 2021 looking forward and zoomatology! Watch it here>> https://t.co/PtfEUPB1hc or listen to podcast on Apple> https://t.co/FHJv01AAbC or Android>https://t.co/Iylluqqeej

Links:

Dr. John Cush RheumNow ( View Tweet)

ACR Convergence 2020 Fireside Chats – Top presentations in nr-axSpA, AS, axial PsA Sponsored by Novartis Medical Affairs Unable to attend all the key sessions at #ACR20? Listen to the experts as they present their views on the top abstracts. https://t.co/r5Cf4WS63s https://t.co/N6QYsofbWe

Links:

Dr. John Cush RheumNow ( View Tweet)
Our latest podcast is up—Lights, Camera, Zoom. We review the news, journal articles and blogs featured on RheumNow this week. Download wherever podcasts are available. https://t.co/8O5AWNa88d

Links:

Dr. John Cush RheumNow ( View Tweet)

Rheumatologists: Record your question or case for the RheumNow podcast. https://t.co/NDhYNX50e2

Links:

Dr. John Cush RheumNow ( View Tweet)

Adherence to Hydroxychloroquine Lowers Lupus Mortality A lupus cohort study from British Columbia, Canada has shown that medication adherence with hydroxychloroquine (HCQ) is associated with a 71% to 83% lower mortality. Read more... https://t.co/luoot7sZZl https://t.co/i2qrqU4EDy

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Convergence 2020 Fireside Chats – top presentations in Still’s disease Sponsored by Novartis Medical Affairs Unable to attend all the key sessions at ACR Convergence 2020? Listen to the experts as they present their views on the top abstracts. https://t.co/MD6lU5oIvy https://t.co/wGVUI5Xjkk

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Convergence 2020 Fireside Chats- top presentations in nr-axSpA, AS, axial PsA and Still’s disease. Sponsored by Novartis Medical Affairs Unable to attend the key sessions at #ACR20? Listen to the experts as they weigh in on the top abstracts. https://t.co/bFrbEGtnw3 https://t.co/dMqhX0f6te

Links:

Dr. John Cush RheumNow ( View Tweet)
Rhapsody Study: IL-1 Inhibition in Recurrent Pericarditis RHAPSODY was a phase 3 multicenter, double-blind, event-driven, randomized-withdrawal trial of rilonacept in 86 patients with recurrent pericarditis Read more: https://t.co/syibq4X7Ps https://t.co/gnxlpOGiHA

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR Guidance on Patient Adherence to Meds--Non-adherence may be the single most untold risk to suboptimal outcomes in the care of musculoskeletal disease. https://t.co/XwxkFz66fv https://t.co/E6W3H56jps

Links:

Dr. John Cush RheumNow ( View Tweet)
Petri et al shows higher HCQ levels associated with reduced thrombosis risk, study of 739 SLE pts - 38 patients (5.1%) had thrombosis. HCQ level lower in thrombosis pts (720 vs 935, p=0.025). 69% decr in VTE when levels >1068 ng/mL vs <648 ng/mL https://t.co/kis5zry7uH

Links:

Dr. John Cush RheumNow ( View Tweet)

Head to RheumNow for our latest Covid-19 articles. https://t.co/TiB7739ONL

Links:

Dr. John Cush RheumNow ( View Tweet)

New download available! H2H comparison chart. https://t.co/w7tQYXn0us

Links:

Dr. John Cush RheumNow ( View Tweet)

Spinal Benefits Seen With Cosentyx in PsA---Secukinumab (Cosentyx) was effective for axial manifestations of psoriatic arthritis in a 52-week multicenter phase III study, investigators reported. https://t.co/OfkQtAO9Gh https://t.co/hs3NaBjLuF

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×